Mixed data doesn't stop this biotech unicorn from plotting a looming PhIII showdown
Samumed has often found it easier to come up with lots more investor cash than consistently positive clinical data. And that odd juxtaposition has never been more apparent than in its latest readout for their lead drug in the pipeline.
Two months after raising a jaw-dropping $438 million at a $12 billion valuation, the biotech has come up with a distinctly mixed batch of Phase IIb data on SM04690. But that won’t stop this unicorn from barreling into a late-stage study in search of an FDA OK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.